Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758348 | 0.94 | MKNK1 (0.37) | MKNK1MAPTACHETHRBBCHE | |
| SCHEMBL21753195 | 0.94 | NOTUM (0.42) | PARP1TNKS2PARP2MKNK1MAPT | |
| SCHEMBL26200405 | 0.90 | MTNR1A (0.45) | PARP1TNKS2PARP2MAPTACHE | |
| SCHEMBL21758323 | 0.89 | MAPT (0.44) | PARP1TNKS2PARP2MAPTACHE | |
| SCHEMBL29899173 | 0.89 | MAPT (0.44) | PARP1TNKS2PARP2MAPTACHE | |
| SCHEMBL21758350 | 0.88 | NOTUM (0.42) | MAPTBRD3 | |
| SCHEMBL21758809 | 0.87 | PRKCI (0.40) | PARP1TNKS2PARP2MKNK1MAPT | |
| SCHEMBL25380545 | 0.86 | MAPT (0.49) | MAPTACHEBCHE | |
| SCHEMBL25381862 | 0.83 | MTNR1A (0.47) | MAPTACHEBCHE | |
| SCHEMBL21753162 | 0.83 | MAPT (0.44) | MAPTACHETHRBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| EP-3841102-B1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2022-09-14 | — | — | EP | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| WO-2020039093-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | AHR, ARNT, NQO1 | PARP1 325/4885TNKS2 941/4885PARP2 286/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | PARP1 325/4885TNKS2 941/4885PARP2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.